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2ABSTRACT
The severity of pneumonia in respiratory syncytial virus (RSV) infection is strongly related to host 
immune response and external factors such as bacteria and environmental chemicals.  We 
investigated the effect of inactivated Streptococcus pneumoniae (ISP) as non-pathogenic particles 
on the severity of pneumonia in RSV-infected mice.  Mice were intranasally exposed to ISP before 
RSV infection.  On day 5 post-infection, we examined the lung tissues, virus titer, and infiltrated 
cells in the lungs.  The ISP did not cause significant histopathological effects on lungs of RSV-
infected mice and reduced virus titer in the lungs.  It reduced the ratio of lymphocyte infiltration 
into the lungs and consequently the ratio of macrophage increased.  In addition, we found that ISP 
increased RANTES level in bronchoalveolar lavage fluid from RSV-infected mice on day 1 post-
infection, but reduced type I interferon levels.  Thus, ISP did not exacerbate pneumonia in RSV 
infection; rather, it might mildly reduce the severity.  We characterize and discuss the inherent 
activity of ISP as non-pathogenic particles inducing the role of RANTES on the pneumonia in RSV 
infection. 
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41. Introduction
Respiratory syncytial virus (RSV, Paramyxoviridae family) causes severe respiratory 
infections in infants, young children, and the elderly worldwide [1-3], and mass infection at schools 
and hospitals due to contact infection in winter [4].  Symptoms of RSV infection have been 
demonstrated to develop mainly as a result of host immune response, and RSV interaction with the 
host immune system is crucial in determining the outcome in diseases such as pneumonia [5].  
Also, external factors such as bacteria and environmental chemical substances are thought to be one 
of the aggravating factors of pneumonia in RSV infection [6-8].  Streptococcus pneumoniae (S. 
pneumoniae) is known as the major cause of death among all respiratory pathogens and causes not 
only respiratory infections such as pneumonia and sinusitis but also meningitis or septicemia.  It 
has been reported that many healthy children and adults possess S. pneumoniae in the upper 
respiratory tract [9].  In the nasopharynx of 45% of children under 3 years of age and up to 20% of 
adults, S. pneumoniae is shown to be colonized [9].  Clinically, concurrent infection with RSV and 
S. pneumoniae was suggested to cause severe pneumonia [10, 11].  In mice, concurrent infection 
by RSV and S. pneumoniae has been also reported to cause severer pneumococcaemia than their 
single infection [12].  In vitro, S. pneumoniae has been shown to adhere to RSV-infected human 
epithelial cells and bind directly to RSV [12, 13].  Thus, the severity of RSV infection is suggested 
to closely relate to the existence of S. pneumoniae in vivo.  However, it is unclear how the 
concurrent infection of RSV and S. pneumoniae exacerbate pneumonia.
Non-microbial substances, such as nanomaterials and irritating gas, have been shown to 
damage lungs and trachea [7, 14].  These substances are also possible factors to exacerbate 
pneumonia in RSV infection.  We previously evaluated the effects of TiO2 nanoparticles, an 
environmental chemical, on RSV infection in mice [7].  In that report, the exposure of mice to 
TiO2 nanoparticles enhanced the levels of interferon (IFN)-γ and chemokine RANTES, 
representative markers of pneumonia, in the bronchoalveolar lavage fluids (BALF) of RSV-infected 
5mice and histopathologically exacerbated pneumonia in RSV-infected mice [7].  The immune 
system of RSV-infected mice has been shown to be significantly affected by TiO2 nanoparticles as 
non-pathogenic particles, resulting in the exacerbation of pneumonia caused by RSV infection.  
This suggested that non-infectious bacteria particles are capable of affecting host immune response 
in RSV infection.  Thus, it is possible that S. pneumoniae, as a non-pathogenic particle itself, 
affects the severity of pneumonia in RSV infection. 
In the present study, we inactivated S. pneumoniae by formalin and investigated its effect 
as non-pathogenic particles on the severity of pneumonia in RSV infection in mice to assess a mode 
of exacerbation of pneumonia in RSV infection by the concurrent infection with S. pneumoniae.  
Mice were intranasally exposed to the inactivated S. pneumoniae (ISP) every other day for five 
days, and then RSV was infected intranasally.  On day 1 or 5 post RSV infection, we 
histopathologically examined lung tissues and immune cells in BALF prepared from RSV-infected 
and uninfected mice, and also evaluated the levels of IFNs and RANTES in the BALF.  We 
characterized the inherent activity of the ISP as non-pathogenic particles on pneumonia in RSV 
infection.
62. Materials and methods
2.1. Animals
We used female BALB/c mice (5 weeks old) purchased from Kyudo Animal Laboratory 
(Kumamoto, Japan).  The mice were housed at five to six per cage under a 12 h light/dark cycle at 
25 ± 2°C.  They were fed a standard solid diet (CRF-1, Oriental Yeast Co., Chiba, Japan), given 
water ad libitum, and acclimated for 7 d before experiments.  Experimental protocols were 
approved by the Animal Experiment Committee of Kyushu University of Health and Welfare, Japan 
(approval numbers: 27-1-31 and 28-1-06) and the animal experimentation guidelines were followed 
in animal studies.
2.2. Virus and cell
A2 strain of RSV was obtained from American Type Culture Collection (Rockville, MD, 
USA).  Human epidermoid carcinoma HEp-2 cells (American Type Culture Collection CCL-23) 
were purchased from Dainippon Pharmaceutical (Osaka, Japan).  HEp-2 cells were maintained in 
Eagle’s minimum essential medium supplemented with heat-inactivated 10% fetal calf serum.  
RSV was grown in HEp-2 cell cultures and viral titers were measured by a plaque method [15].  
The virus yields were expressed as plaque-forming units per milliliter (PFU/mL) [15].  In vivo 
experiments, HEp-2 cells were used for titration of the virus yield in the lungs of mice.  
2.3. S. pneumoniae and its inactivation
S. pneumoniae (ATCC49619, serotype 19F) was purchased from American Type Culture 
Collection (Rockville, MD, USA) and grown on 5% sheep blood agar medium at 37℃.  The S. 
7pneumoniae grown in the agar medium were collected and suspended in phosphate-buffered saline 
(PBS).  The concentration of S. pneumoniae in the suspension was measured by counting colony-
forming units (CFU).  The S. pneumoniae suspension at 1.0 × 108 CFU/mL was centrifuged at 
2150 × g, then the precipitated S. pneumoniae was suspended and inactivated in 2% formalin 
solution for 60 h at room temperature.  The ISP was centrifuged at 2150 × g, and then the 
precipitated ISP was twice rinsed with PBS.  The rinsed S. pneumoniae was suspended in PBS and 
stored at -30℃.  Before animal experiments, the stored ISP was rinsed three times with PBS and 
suspended in PBS at 1.0 × 108 CFU/mL.  The suspension of 0.1 mL was used for the intranasal 
exposure of mice.  The remaining formalin in the ISP suspension was determined by Schiff’s 
reagent according to the manufacturer’s instructions (Nacalai Tesque, Kyoto, Japan).    
2.4. Animal tests
Mice were intranasally exposed to 0.1 mL of a suspension of ISP at 1.0 × 108 CFU/mL 
once daily on days 1, 3, and 5 before RSV infection under anesthesia with ketamine and xylazine at 
40 and 6 μg/kg of body weight, respectively.  In the control group, mice were intranasally exposed 
to PBS (0.1 mL) under anesthesia.  RSV (1.0 × 106 PFU/100 µL) was intranasally infected to the 
ISP-exposed mice under anesthesia [15].  In the uninfected group, mice were intranasally given 
PBS.  On day 1 or 5 post-infection, lungs and BALF from the mice were prepared under 
anesthesia. 
2.5. Histopathological methods
For histopathological examination of lungs, lungs were removed from mice on day 5 post-
infection under anesthesia.  Briefly, 10% buffered formalin solution was injected into lungs via 
trachea and then the removed lungs were immersed in the solution and fixed.  The fixed tissue was 
8then embedded in paraffin, sectioned at a thickness of 4 μm, and stained with hematoxylin and 
eosin.  The samples were observed under a microscope (× 100) and scored.  To score the 
inflammation of the lungs, 4 lobes of the lung sections were quantitatively analyzed.  The degree 
of thickness of the alveolar wall, infiltration of inflammatory cells into alveoli, and lymphocyte 
infiltration around the pulmonary artery were graded on a scale of 0−4 (0, absent; 1, mild; 2, 
moderate; 3, severe; 4, very severe) as described previously [16].  The total histopathological lung 
inflammation score comprises the sum of the scores for four lobes (maximum score is 16).  In each 
group, the lungs of two to five mice (control and ISP-exposed mice without RSV infection: n = 2, 
RSV-infected mice with and without exposure of ISP: n = 5) were evaluated, and the average value 
was calculated.
2.6. IFNs and RANTES levels in BALF
BALF was prepared from RSV-infected and uninfected mice on day 1 and day 5 post-
infection.  Briefly, BALF was obtained from the mice under anesthesia by instilling 0.8 mL of 
cold PBS into the lungs and aspirating it from the trachea using a tracheal cannula [15].  The 
obtained BALF was centrifuged at 160 × g at 4℃ for 10 min.  The supernatant was stored at -80℃ 
until the use for enzyme-linked immunosorbent assay (ELISA).  The levels of IFN-α, IFN-β, IFN-
γ, and RANTES (CCL5) in BALF were measured using ELISA kits (VeriKine, PBL Assay 
Science., Piscataway, NJ, USA; Quantikine, R&D Systems, Inc., Minneapolis, MN, USA; Ready-
set-go, eBioscience Inc., San Diego, CA, USA; and Quantikine, R&D Systems, Inc., Minneapolis, 
MN, USA; respectively) according to the manufacturer’s instructions.  The lower limits of 
detection of the kits are 12.5 pg/mL for IFN-α, 1.89 pg/mL for IFN-β, 15 pg/mL for IFN-γ, and 2 
pg/mL for RANTES.  The intra- and inter-assay coefficients of variation for the ELISA results 
were less than 10%.
92.7. Virus titration
Virus yields in the lungs were determined in RSV-infected mice.  The lungs were 
removed under anesthesia on day 5 after infection.  The removed lungs were immediately frozen 
in liquid N2 and stored at -80°C until use.  The frozen lungs were homogenized with cold quartz 
sand in a homogenizer [15].  The homogenate was centrifuged at 480 × g at 4℃ for 15 min.  
Virus yield [PFU/lung (n = 5)] in the supernatant was determined by the plaque assay on Hep-2 
cells [15, 17].  
2.8. Analysis of bronchoalveolar lavage cells
Bronchoalveolar lavage cells were collected from each BALF by centrifugation at 160 × g 
for 10 min.  The collected cells were suspended in PBS, counted using a hemocytometer, and then 
expressed as the total cell number per µL of each BALF.  Also, the cells were smeared onto slides, 
stained with Wright-Giemsa staining solution (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 
3−4 min, and then washed with water until the edge was faintly pinkish red.  Finally, the cell 
morphology was histopathologically observed under a microscope (× 400), and macrophages, 
neutrophils, and lymphocytes were identified and counted.  Their ratios were expressed as 
percentages of 200 cells per specimen (control: n = 2, ISP-exposed mice without RSV infection: n = 
3, others: n = 6).    
2.9. Statistical analysis
Comparisons of the histopathological scores of the lungs, the levels of IFNs and RANTES 
in BALF, the pulmonary viral titers, and the percentages of bronchoalveolar lavage cells were 
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carried out using the Student’s t-test.  A value of P < 0.05 or less was considered statistically 
significant. 
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3. Results
3.1. Effect of ISP on severity of pneumonia by RSV infection
S. pneumoniae was inactivated by formalin to assess the severity of pneumonia in RSV 
infection by S. pneumoniae as non-pathogenic particles.  The ISP was suspended in PBS, and mice 
were intranasally exposed to the ISP once daily on days 1, 3, and 5 before RSV infection.  The 
inactivation of S. pneumoniae was confirmed by a growth assay on blood agar medium, and no 
morphological changes of S. pneumoniae by formalin treatment were observed under a microscope 
(data not shown).  When examined by Schiff’s reagent, no remaining formalin was detected (data 
not shown).  Thus, it was confirmed that S. pneumoniae is completely inactivated and the toxicity 
of the remaining formalin in suspension was excluded.  In fact, no abnormal behavior or dystrophy 
of mice was observed after exposure of the ISP in mice.
Mice exposed or unexposed to the ISP were intranasally infected with RSV at 0 or 1.0 × 
106 PFU.  On day 5 post-infection, the lung tissues of RSV-infected mice were histopathologically 
analyzed.  Fig. 1 shows representative lung tissues of mice exposed or not exposed to ISP with or 
without RSV infection.  In the exposed mice without RSV infection, no obvious changes in the 
lung tissues due to ISP were observed, as well as in the unexposed mice without RSV infection 
(Fig. 1A and 1B).  On the other hand, in the unexposed mice with RSV infection, typical features 
of pneumonia, such as degeneration of the bronchial epithelium, infiltration of lymphocytes, and 
neutrophils, were observed (Fig. 1C).  Similar features of pneumonia were also observed in ISP-
exposed mice with RSV infection, but no noticeable differences were observed between RSV-
infected mice with and without ISP exposure (Fig. 1C and 1D).  
We quantitatively compared the severity of pneumonia in the four lung lobes of each RSV-
infected or -uninfected mouse with or without exposure to ISP.  As indexes of pneumonia, the 
thickness of the alveolar wall, infiltration of inflammatory cells into alveoli, and infiltration of 
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lymphocytes around the pulmonary artery were scored.  As shown in Table 1, although the indexes 
in RSV-infected mice with exposure to ISP were lower than those in RSV-infected mice without the 
exposure, there were no significant differences.  In RSV-uninfected mice with and without the 
exposure, histopathological changes due to the exposure to ISP were not significantly observed.  
Thus, no obvious exacerbation of pneumonia in RSV-infected mice was histopathologically 
observed due to exposure to ISP.                   
3.2. Effects of ISP on IFN-γ production in BALF from RSV-infected mice
IFN-γ, a Th1 cytokine, in BALF of RSV-infected mice is a sensitive marker of the severity 
of pneumonia by RSV infection [18].  As shown in Fig. 2, we compared IFN-?? levels in the 
BALF prepared from RSV-infected mice with and without the exposure of ISP on day 5 post RSV 
infection.  In the RSV-uninfected mice, the IFN-γ levels were not detected even by the exposure to 
ISP.  On the other hand, in the RSV-infected mice without the exposure of ISP, IFN-γ level 
increased remarkably as reported previously [6, 7, 15].  Although the exposure of ISP slightly 
reduced the IFN-γ level as compared with that in RSV-infected mice without the exposure, the 
slight reduction was not statistically significant.  Thus, it was suggested that the exposure of ISP 
did not affect the exacerbation of pneumonia in RSV infection.
3.3. Influence of ISP on virus titer of lungs of RSV-infected mice 
The virus titer in the lungs of RSV-infected mice has been shown to correlate with the 
severity of pneumonia caused by RSV infection [8, 15].  We compared the viral titers of lungs 
prepared from RSV-infected mice with and without the exposure to ISP on day 5 post RSV 
infection.  As shown in Fig. 3, the exposure to ISP significantly reduced the virus titer of lungs of 
RSV-infected mice.  Thus, ISP was suggested to be effective in alleviating pneumonia in RSV-
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infected mice.  However, this result did not sufficiently reflect the histopathological results, as 
shown in Fig. 1 and Table 1. 
3.4. Effect of ISP on infiltrated cells in lungs of RSV-infected mice 
RSV interaction with the host immune system is crucial in deteriorating pneumonia [5, 6, 
15].  To estimate the immune status of lungs of RSV-infected mice exposed to ISP, we 
histopathologically characterized and compared the infiltrated cells in BALF prepared from RSV-
infected mice with and without exposure to ISP.  Fig. 4 shows the representative infiltrated cells in 
the BALF of RSV-infected or uninfected mice exposed or not to ISP.  In the RSV-uninfected mice 
exposed (Fig. 4B) or not exposed (Fig. 4A) to ISP, most cells observed were mononuclear lineage 
cells regardless of the exposure, and the exposure to ISP did not remarkably affect the population of 
infiltrated cells in RSV-uninfected mice.  In the BALF of RSV-infected mice without exposure to 
ISP (Fig. 4C) the population of lymphocytes increased, and the population seemed to be larger than 
that in the BALF of RSV-infected mice with exposure to ISP (Fig. 4D).  In the RSV-infected mice 
exposed to ISP (Fig. 4D), the ratio of mononuclear lineage cells in the infiltrated cells seemed to be 
larger than that in the RSV-infected mice without the exposure.   
We histopathologically identified lymphocytes, macrophages, neutrophils, and the other 
cells as cells infiltrated into BALF and examined their ratios in total cells in BALF, as shown in 
Table 2.  In the RSV-uninfected mice without the exposure to ISP, the total number of infiltrated 
cells was very low (91.7 ± 8.3 cells/µL), but the exposure to ISP noticeably increased the total 
number of infiltrated cells (327.8 ± 92.2 cells/µL).  In the either case, most infiltrated cells were 
macrophages (100% and 99.8 ± 0.2%).  However, in RSV-infected cells with and without the 
exposure, the total numbers of infiltrated cells (784.7 ± 223.4 and 972.2 ± 168.0 cells/µL, 
respectively) were similar, and their numbers were larger than that in the RSV-uninfected mice with 
the exposure (327.8 ± 92.2 cells/µL).  In RSV-infected mice with and without the exposure, the 
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large populations of infiltrated cells were lymphocytes and macrophages, and the ratios of 
neutrophils and other cells were very low.  The actual numbers of macrophages in RSV-infected 
mice with (541 cells/µL) and without (465 cells/µL) the exposure were similar and slightly higher 
than that in RSV-uninfected mice with the exposure (327 cells/µL).  In RSV-infected mice, the 
exposure reduced the ratio of lymphocytes in the infiltrated cells but remarkably increased that of 
macrophages.  Thus, it was possible that ISP mainly interfered with the infiltration of lymphocytes 
into the lungs of RSV-infected mice, resulting in the rise of ratio of macrophage population.  As a 
result, the exposure to ISP was effective in reducing lymphocyte infiltration into the lungs of RSV-
infected mice.  
3.5. Effects of ISP on the levels of type I IFNs and RANTES in BALF of RSV-infected mice
     Type I IFNs are important immune mediators with antiviral activity, have been shown to 
be produced by live S. pneumoniae-infected macrophages, and positively regulate RANTES 
production in macrophages and cocultured alveolar epithelial cells in vitro [19].  Also, type I IFNs 
have been shown to control RANTES production during pneumococcal pneumonia in vivo [19].  
Further, RANTES has been shown to facilitate macrophage infiltration in the early phase of injury 
[20].  Type I IFNs and RANTES are known to be related to the activation and infiltration of 
macrophages.  Thus, in order to elucidate the relative increase of macrophage population in lungs 
of RSV-infected mice by exposure to ISP, we examined IFN-α and β and RANTES levels in BALF 
prepared from RSV-infected and uninfected mice with or without the exposure (Fig. 5).  On day 5 
post-infection, no detectable IFN-α and β were observed in RSV-infected and -uninfected mice 
regardless of the exposure to ISP (Figs. 5A and 5B) and RANTES was less detectable in any RSV-
infected and uninfected mice, either (Fig. 5C).  As type I IFNs are mainly produced in early stage 
of microbial infection [19], we also prepared BALF on day 1 post-infection to examine the 
production of IFN-α and β and RANTES.  On the day 1, IFN-α and β and RANTES were 
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noticeably detected in RSV-infected mice regardless of the exposure, but they were not detectable 
in the RSV-uninfected mice (Fig. 5).  In the RSV-infected mice, exposure to ISP reduced the 
levels of IFN-α and β in BALF, although the reduction of IFN-β was statistically significant but that 
of IFN-α was not (Figs. 5A and 5B).  However, the exposure increased RANTES level although it 
was not statistically significant (Fig. 5C).  ISP exposure obviously affected the levels of IFN-α and 
β and RANTES in RSV-infected mice, but did not produce IFN-α and β and RANTES in RSV-
uninfected mice.  Thus, the rise of RANTES level in the early stage of RSV infection by exposure 
to ISP might contribute to the rise of ratio of macrophage population in the lungs.                 
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4. Discussion
Previously S. pneumoniae was pathologically suggested to exacerbate RSV infection not 
only in vitro but also in vivo [8, 10-12].  Also, host immune response to RSV infection has been 
demonstrated to greatly contribute to the exacerbation of pneumonia in RSV infection [5-7, 15].  
However, in concurrent infection by RSV and S. pneumoniae, the mode of exacerbation of 
pneumonia by S. pneumoniae was unclear.  Recently, we found that exposure of mice to TiO2 
nanoparticles as nonpathogenic particles exacerbates the pneumonia of RSV-infected mice, and that 
the exacerbation was largely responsible for the overreaction of the immune system of RSV-
infected mice to TiO2 nanoparticles [7].  Thus, in this study, we investigated the effects of ISP as 
non-pathogenic particles on the severity of pneumonia in RSV-infected mice to assess a mode of 
exacerbation of RSV infection by concurrent infection with S. pneumoniae.  We demonstrated that 
the ISP as non-pathogenic pneumococcal particles did not exacerbate pneumonia in RSV infection, 
but rather, it mildly reduced the severity.  
In this study, S. pneumoniae was inactivated by formalin.  However, no remaining 
formalin in the suspension of ISP was detected, and abnormal behavior of the mice was not 
observed.  Histopathological analysis of lung tissues and bronchoalveolar lavage cells showed that 
there was no difference between RSV-uninfected mice with and without exposure to ISP (Figs. 1 
and 3).  Thus, the significant toxicity of formalin was not observed in mice.  In our RSV infection 
model in mice, mice were intranasally exposed to ISP at 1.0 ×107 CFU/0.1 mL once daily on days 1, 
3, and 5 before RSV infection.  The dose of ISP used was an immunologically active amount in 
mice, because a sufficient TNF-α level as an initial immune response was detected in the BALF 
prepared from ISP-exposed mice (data not shown).  Further, as shown in Table 2, the exposure to 
ISP noticeably increased the total number of infiltrated cells in BALF of RSV-uninfected mice.  
Thus, the dose of ISP was indicated to be sufficiently effective in producing an immunological 
action in RSV-infected mice in this study.  It was confirmed that the ISP did not exacerbate 
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pneumonia in RSV infection, even though immunological response by the ISP occurred in mice.       
Significant effects were not histopathologically observed in the lungs of RSV-infected mice 
exposed to ISP on day 5 post-infection (Fig. 1 and Table 1).  Also, the IFN-γ level in the BALF of 
RSV-infected mice, reflecting the exacerbation of pneumonia in RSV-infected lungs, was not 
significantly augmented by the exposure to ISP (Fig. 2).  The total number of cells infiltrated into 
BALF of RSV-infected mice after exposure to ISP was not significantly higher than that in RSV-
infected mice without the exposure (Table 2).  These results indicated that the ISP did not 
exacerbate pneumonia in RSV infection.  The ISP as non-pathogenic particles was found not to be 
a deleterious factor in pneumonia in RSV-infected mice.  In concurrent infections of RSV and S. 
pneumoniae, it was suggested that live S. pneumoniae and its growth in vivo are important to 
exacerbate pneumonia in RSV infection.  In our study, RSV infection was preceded by ISP 
exposure, because many healthy children and adults possess S. pneumoniae in the upper respiratory 
tract as described previously [9].  However, it may be clinically possible that S. pneumoniae 
infection occurs after RSV infection.  Thus, it would be also interesting to compare the clinical and 
immunological effects of RSV-infected mice before and after the exposure to ISP.
As shown in Table 2, the exposure of ISP significantly reduced the ratio of lymphocytes in 
the total infiltrated cells of BALF while it increased the ratio of macrophages.  In BALF of RSV-
uninfected mice, the exposure also produced the dominant infiltration of macrophages.  The 
increase in the macrophage population in BALF of RSV-infected mice not only without but also 
with the exposure to ISP might reflect the strong ability of ISP to infiltrate macrophages in mice.  
Some researchers have reported that macrophages are important in the host defense mechanism 
against live S. pneumoniae [19, 21, 22].  Even against the exposure to ISP, macrophages might 
play a significant role in the immunity of host defense.             
In RSV infection, macrophages have been shown to be pathologically major cells that can 
produce IFN-γ [5].  Table 2 shows that the exposure to ISP slightly decreased the total number of 
infiltrated cells in the BALF of RSV-infected mice but significantly increased the ratio of 
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macrophages in the total infiltrated cells.  As a result, the substantial number of macrophages in 
total infiltrated cells in the BALF of RSV-infected mice with the exposure did not seem to be 
remarkably different from that in the RSV-infected mice without the exposure.  Thus, IFN-γ levels 
in the BALF of RSV-infected mice might not be significantly different regardless of the exposure, 
as shown in Figure 2.        
The exposure to ISP reduced the virus titer in the lungs of RSV-infected mice (Fig. 3).  In 
RSV infection, cellular immunity mediated by lymphocytes, especially T cells, plays a critical role 
in virus elimination, and its overreaction causes the exacerbation of pneumonia [5, 6].  However, 
the exposure to ISP was not able to exacerbate pneumonia in RSV infection as described above.  
This suggested that cellular immunity was not sufficiently activated by ISP in RSV-infected mice.  
Also, the ISP significantly reduced the population of lymphocytes in BALF of RSV-infected mice 
and significantly increased that of macrophages (Table 2).  Thus, it is likely that the reduction of 
lymphocyte populations by the exposure promoted the insufficient activation of cellular immunity 
as compared with the case without the exposure.  Live S. pneumoniae has been demonstrated to 
promote the production of type I IFNs from macrophages [19].  However, in our study, exposure 
to ISP was not effective in producing IFN-α and β in BALF of RSV-uninfected mice and the levels 
of IFN-α and β in the BALF of RSV-infected mice were reduced by the exposure, as shown in Fig 
5.  ISP was not a stimulator of type I IFN production in vivo.  The reduction of virus titer in the 
lungs of RSV-infected mice by exposure to ISP was suggested not to be due to the antiviral activity 
of type I IFNs.  RANTES has been shown to act as a chemoattractant for NK cells, which are 
important in viral clearance in the early stage of infection [23].  Also, it has been reported to block 
apoptosis of alveolar macrophages [24] and to be involved in antimicrobial activity by inducing NO 
in macrophages [25].  These results indicate that RANTES may indirectly possess antiviral 
activity.  Thus, the rise of RANTES level in the BALF of RSV-infected mice with exposure to ISP 
might contribute to the reduction of virus titer in the lungs.   
In this study, the ISP as non-pathogenic pneumococcal particles was demonstrated not to be 
19
the deleterious factor of pneumonia in RSV-infected mice, but rather it was possible that the ISP 
slightly ameliorated pneumonia.  It has been recently reported that a higher nasopharyngeal 
pneumococcal density was correlated with a less severe course of disease when pneumococcus is 
present in patients [26].  Thus, it may be possible that ISP is useful to alleviate or retard the 
development of pneumonia caused by RSV infection through the avoidance of immunological 
overreaction by activation of cellular immunity.   
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Figure Legends
Fig. 1. Histopathology of lung tissues of RSV-infected mice exposed to ISP.  On day 5 post RSV 
infection, lungs were prepared from RSV-uninfected (A: control) and -infected (C: RSV) mice, and 
also from ISP-exposed mice to (D: RSV + ISP) and not (B: ISP) RSV infection.  The lung tissues 
were stained with hematoxylin and eosin, and then observed under a microscope (× 100).  Open 
arrowheads indicate thickened alveolar walls.  Closed arrowheads indicate mononuclear cells 
infiltrated into alveoli.  
Fig. 2. Effect of ISP on IFN-γ production in BALF of RSV-infected and -uninfected mice.  Mice 
were intranasally exposed to ISP and then infected with RSV.  On day 5 post-infection, BALF was 
prepared, and the IFN-γ concentration in the BALF was determined by ELISA as described in 
Materials and Methods.  Control, RSV-uninfected mice; ISP, ISP-exposed mice without RSV 
infection; RSV, RSV-infected mice; RSV + ISP, ISP-exposed mice with RSV infection.  The data 
represent mean ± standard deviation of values of 2−6 mice (control: n = 2, others: n = 6/group).  
Fig. 3. Effect of ISP exposure on RSV yield in the lungs of RSV-infected mice on day 5 post-
infection.  RSV titers in the lungs were determined by plaque assay.  RSV, RSV-infected mice; 
RSV + ISP, mice with RSV infection exposed to ISP.  The data represents mean ± standard 
deviation of 5 mice/group.  *Significantly different from control at P < 0.05 (Student’s t-test).
Fig. 4. Histopathology of infiltrated cells in BALF of RSV-infected mice with and without the 
exposure to ISP.  On day 5 after RSV infection, BALF was prepared from RSV-uninfected (A: 
control) and -infected (C: RSV) mice, and also from ISP-exposed mice with (D: RSV + ISP) and 
without (B: ISP) RSV infection.  Bronchoalveolar lavage cells were stained with Wright-Giemsa 
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solution and then observed under a microscope (× 400).  Open arrowheads indicate mononuclear 
lineage cells.  Closed arrowheads indicate lymphocytes.
Fig. 5. Effect of ISP on type I IFNs and RANTES productions in BALF of RSV-infected and 
uninfected mice.  Mice were intranasally exposed to ISP and then infected with RSV.  On day 1 
and day 5 post-infection, BALF was prepared, and the IFN-α (A) and β (B) and RANTES (C) 
concentrations in the BALF were determined by ELISA as described in Materials and Methods.  
Control, RSV-uninfected mice; ISP, ISP-exposed mice without RSV infection; RSV, RSV-infected 
mice; RSV + ISP, ISP-exposed mice with RSV infection.  The data represent mean ± standard 
deviation of values of 2 or 6 mice (control: n = 2, others: n = 6/group).  
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Table 1
Lung inflammation score of mice on day 5 after RSV infection.
Evaluation item                      Inflammation scorea
Control ISP RSV RSV + ISP
Thickness of alveolar wall 0 0 8.6 ± 1.02 8.0 ± 1.10
Infiltration of inflammatory cells
into alveoli 0       2.0 8.2 ± 0.75 7.4 ± 1.36
Lymphocyte infiltration around
pulmonary artery 0        0 8.2 ± 0.75 7.2 ± 1.17
Control = RSV-uninfected mice; ISP = ISP-exposed mice without RSV infection; RSV = RSV-infected mice;
RSV + ISP = ISP-exposed mice with RSV infection.
aLung tissues were scored in 5 grades of 0 to 4 (0, absent; 2, moderate; 3, severe; 4, very severe) for each of 4 lobes, 
and the extent of inflammation was evaluated by totaling them.  Data represents mean ± standard deviation of 2 or 5 mice 
(Control and ISP, n = 2 and RSV and RSV + ISP, n = 5).  
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Table 2
Analysis of bronchoalveolar lavage cells on day 5 after RSV infection.
Treatment Lymphocytes (%) Macrophages (%) Neutrophil (%) Others (%) Total cell number/µL
Control 0 100 0 0 91.7 ± 8.3
ISP 0.2 ± 0.2  99.8 ± 0.2 0 0 327.8 ± 92.2
RSV 49.7 ± 6.8  47.8 ± 7.0 2.5 ± 1.8 0 972.2 ± 168.0
RSV + ISP 27.9 ± 0.2*  68.9 ± 6.3* 3.2 ± 1.6 0 784.7 ± 223.4
Control = RSV-uninfected mice; ISP = ISP-exposed mice without RSV infection; RSV = RSV-infected mice;
RSV + ISP = ISP-exposed mice with RSV infection.  
Data represent mean ± standard deviation of 2-6 mice (Control, n = 2; ISP, n = 3; RSV and RSV + ISP, n = 6).    
*Statistically different from RSV-infected group at P < 0.01 by Student’s t-test.
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